Standard BioTools (LAB) Set to Announce Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Standard BioTools to post earnings of ($0.09) per share for the quarter. Standard BioTools has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Standard BioTools (NASDAQ:LAB) last issued its earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. The company had revenue of $28.19 million for the quarter, compared to analysts’ expectations of $28.00 million. On average, analysts expect Standard BioTools to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Standard BioTools Stock Performance

Shares of NASDAQ LAB opened at $2.48 on Wednesday. Standard BioTools has a one year low of $1.46 and a one year high of $3.16. The company’s fifty day moving average is $2.61 and its two-hundred day moving average is $2.35.

Insider Activity at Standard BioTools

In other news, Director Casdin Partners Master Fund, L bought 250,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was purchased at an average price of $2.57 per share, with a total value of $642,500.00. Following the purchase, the director now owns 11,496,525 shares of the company’s stock, valued at approximately $29,546,069.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 53.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LAB has been the subject of several research reports. Jefferies Financial Group initiated coverage on Standard BioTools in a research note on Thursday, April 4th. They set a “buy” rating and a $3.25 price target for the company. TD Cowen initiated coverage on Standard BioTools in a research note on Tuesday, April 16th. They set a “buy” rating and a $3.50 price target for the company.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.